Guidelines for Waiting Periods Between MBI Examination and Other Imaging Procedures
| Modality | Procedure | Administered dose | Recommended waiting period |
| CT | With or without contrast | None | |
| MRI | With or without contrast | None | |
| PET | All radiopharmaceuticals | None | |
| Nuclear medicine | 99mTc-sestamibi for parathyroid (or cardiac rest only) studies | 370–1,110 MBq (10–30 mCi) | None* |
| 99mTc-radiopharmaceuticals, intravenous or oral | >740 MBq (20 mCi) | >12 h | |
| >370 MBq (10 mCi) | >24 h | ||
| >185 MBq (5 mCi) | >24 h | ||
| <185 MBq (5 mCi) | >36 h | ||
| 99mTc-sulfur colloid (sentinel node) | <19 MBq (500 μCi) | >24 h | |
| 123I-based radiopharmaceuticals | >370 MBq (10 mCi) | None | |
| <37 MBq (1 mCi) | >24 h | ||
| 111In- and 67Ga-based radiopharmaceuticals | None |
These are general guidelines and in some cases may overestimate waiting period needed, depending on biologic distribution of radiopharmaceutical.
↵* May consider combining dose administration. In cases of prior administration of 99mTc-sestamibi for cardiac or parathyroid studies, reduced (or no dose) of 99mTc-sestamibi may be used, depending on residual activity from prior study.